Results 31 to 40 of about 47,434 (363)

What information could the main actors of liquid biopsy provide? A representative case of non-small cell lung cancer (NSCLC) [PDF]

, 2018
In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells
Manicone, M., Mariotta, S., Pezzuto, A., Ricci, A., Rossi, Elisabetta, Scaini, M. C., Zamarchi, R.   +6 more
core   +1 more source

ctDNA as a Cancer Biomarker: A Broad Overview

Critical Reviews in Oncology/Hematology, 2020
Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of treatment, and prognosis: the so-called liquid biopsy. Liquid biopsy is a minimally invasive approach and presents the sum of ctDNA from primary and secondary tumor sites. It has been
Pessoa, Luciana Santos, Heringer, Manoela, Ferrer, Valéria Pereira   +2 more
openaire   +5 more sources

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution' [PDF]

, 2017
No abstract ...
Daniel J Murphy, HG Colt, J Mazieres, JC Wan, JP Pignon, K Suzawa, Kevin G Blyth, L Calman, M Jamal-Hanjani, M Schuler, TD Crabtree, WC Hanna   +11 more
core   +1 more source

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

npj Breast Cancer, 2023
Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future ...
S. Stecklein, B. Kimler, R. Yoder, Kelsey Schwensen, J. Staley, Q. Khan, A. O'Dea, Lauren E Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, H. Pathak, A. Godwin, Priyanka Sharma   +15 more
semanticscholar   +1 more source

DNA Oxidation Photoinduced by Norharmane Rhenium(I) Polypyridyl Complexes: Effect of the Bidentate N,N′-Ligands on the Damage Profile [PDF]

, 2018
ReI-polypyridyl complexes have interesting and distinctive photochemical and photosensitizing properties. This work describes the capability to induce (or photoinduce) DNA damage of three ReI-complexes with a naturally occurring alkaloid called ...
Ahmad, Balasingham, Balón, Blasius, Boerner, Boiteux, Bonett, Cao, Coggan, Copeland, Crespy, Daley, de Souza, Dhar, Dong, Epe, Epe, Erkkila, Etienne, Feliz, Fernández-Moreira, Friedman, Gasser, Ghesquière, Gonzalez, Gonzalez, Gonzalez, Gonzalez, Gonzalez, Gonzalez, Hayashi, Häring, Kaplanis, Kastl, Kaulage, Knopf, Krokan, Kumar, Kydonaki, Lakowicz, Lee, Leonidova, Lhiaubet-Vallet, Lo, Maisuls, Maisuls, Maisuls, Mari, Marker, Maron, Martí, McKenzie, McKinley, Müller, Ng, Niesel, Paul, Pohl, Pyle, Ragone, Rasse-Suriani, Ruiz, Ruiz, Ruiz, Salditt, Schatzschneider, Schmidt, Schutte, Schäfer, Shahabadi, Smith, Song, Stemp, Stoeffler, Sun, Taira, Thornton, Vignoni, Wilson, Wolfe, Zeglis, Ziessel, Zobi   +82 more
core   +1 more source

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2023
Circulating tumor DNA (ctDNA), i.e., DNA shed from tumor cells into the bloodstream, is emerging as one of the most useful plasma biomarkers in patients with multiple types of cancer, including patients with non-small cell lung cancer (NSCLC).
M. Duffy
semanticscholar   +1 more source

Application Value of ctDNA-based MRD Dedection 
in Early Stage Non-small Cell Lung Cancer after Radical Surgery

Chinese Journal of Lung Cancer, 2021
Lung cancer is the most common malignant tumor in the world, among which non-small cell lung cancer (NSCLC) accounts for about 85% of the total number of lung cancers.
Shihua DOU, Hongsheng XIE, Lin YANG
doaj   +1 more source

The importance of circulating tumor products as „liquid biopsies” in colorectal cancer [PDF]

, 2018
Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Calborean, Veronica, Miscoci, Alina, Pirvu, Cristian D., Pădureanu, Vlad, Rogoveanu, Otilia C., Streba, Costin T., Vere, Cristin C.   +6 more
core   +4 more sources

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Cancers, 2022
Liquid biopsy has improved significantly over the last decade and is attracting attention as a tool that can complement tissue biopsy to evaluate the genetic landscape of solid tumors. In the present study, we evaluated the usefulness of liquid biopsy in daily oncology practice in different clinical contexts.
Josep Gumà, Karla Peña, Francesc Riu, Carmen Guilarte, Anna Hernandez, Clara Lucía, Francisca Martínez-Madueño, Maria José Miranda, Inés Cabezas, Marc Grifoll, Sergio Peralta, Sara Serrano, Félix Muñoz, Lola Delamo, Barbara Roig, Joan Borràs, Joan Badia, Marta Rodriguez-Balada, David Parada   +18 more
openaire   +2 more sources

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal [PDF]

Cancers, 2022
The treatment of locally advanced rectal cancer (LARC) has evolved during the last decades, but recurrence remains a problem. Circulating tumor DNA (ctDNA) may result in an individualized treatment approach with improved survival and quality of life, but diverging results impede further development.
Edina Dizdarevic, Torben Hansen, Anders Jakobsen   +2 more
openaire   +3 more sources